Kuiper, J. L., Lind, J. S. W., Groen, H. J. M., Roder, J., Grigorieva, J., Roder, H., . . . Smit, E. F. (2012). VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. Nature Publishing Group.
Chicago-stil citatKuiper, J L., J S W. Lind, H J M. Groen, J. Roder, J. Grigorieva, H. Roder, A M C. Dingemans, och E F. Smit. VeriStrat(®) Has Prognostic Value in Advanced Stage NSCLC Patients Treated with Erlotinib and Sorafenib. Nature Publishing Group, 2012.
MLA-referensKuiper, J L., et al. VeriStrat(®) Has Prognostic Value in Advanced Stage NSCLC Patients Treated with Erlotinib and Sorafenib. Nature Publishing Group, 2012.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.